292 related articles for article (PubMed ID: 21369346)
1. Efficacy of CMX001 as a prophylactic and presymptomatic antiviral agent in New Zealand white rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Lampert B; Foster S; Robertson A; Painter G; Moyer RW
Viruses; 2011 Feb; 3(2):63-82. PubMed ID: 21369346
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of CMX001 as a post exposure antiviral in New Zealand White rabbits infected with rabbitpox virus, a model for orthopoxvirus infections of humans.
Rice AD; Adams MM; Wallace G; Burrage AM; Lindsey SF; Smith AJ; Swetnam D; Manning BR; Gray SA; Lampert B; Foster S; Lanier R; Robertson A; Painter G; Moyer RW
Viruses; 2011 Jan; 3(1):47-62. PubMed ID: 21373379
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of delayed brincidofovir treatment against a lethal rabbitpox virus challenge in New Zealand White rabbits.
Grossi IM; Foster SA; Gainey MR; Krile RT; Dunn JA; Brundage T; Khouri JM
Antiviral Res; 2017 Jul; 143():278-286. PubMed ID: 28392420
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and pharmacokinetics of brincidofovir for the treatment of lethal rabbitpox virus infection: a model of smallpox disease.
Trost LC; Rose ML; Khouri J; Keilholz L; Long J; Godin SJ; Foster SA
Antiviral Res; 2015 May; 117():115-21. PubMed ID: 25746331
[TBL] [Abstract][Full Text] [Related]
5. Co-administration of the broad-spectrum antiviral, brincidofovir (CMX001), with smallpox vaccine does not compromise vaccine protection in mice challenged with ectromelia virus.
Parker S; Crump R; Foster S; Hartzler H; Hembrador E; Lanier ER; Painter G; Schriewer J; Trost LC; Buller RM
Antiviral Res; 2014 Nov; 111():42-52. PubMed ID: 25128688
[TBL] [Abstract][Full Text] [Related]
6. Smallpox vaccination and adverse reactions. Guidance for clinicians.
Cono J; Casey CG; Bell DM;
MMWR Recomm Rep; 2003 Feb; 52(RR-4):1-28. PubMed ID: 12617510
[TBL] [Abstract][Full Text] [Related]
7. Coadministration of cidofovir and smallpox vaccine reduced vaccination side effects but interfered with vaccine-elicited immune responses and immunity to monkeypox.
Wei H; Huang D; Fortman J; Wang R; Shao L; Chen ZW
J Virol; 2009 Jan; 83(2):1115-25. PubMed ID: 19004937
[TBL] [Abstract][Full Text] [Related]
8. A mouse model of lethal infection for evaluating prophylactics and therapeutics against Monkeypox virus.
Stabenow J; Buller RM; Schriewer J; West C; Sagartz JE; Parker S
J Virol; 2010 Apr; 84(8):3909-20. PubMed ID: 20130052
[TBL] [Abstract][Full Text] [Related]
9. Buccal viral DNA as a trigger for brincidofovir therapy in the mousepox model of smallpox.
Crump R; Korom M; Buller RM; Parker S
Antiviral Res; 2017 Mar; 139():112-116. PubMed ID: 28039021
[TBL] [Abstract][Full Text] [Related]
10. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox.
Adams MM; Rice AD; Moyer RW
J Virol; 2007 Oct; 81(20):11084-95. PubMed ID: 17686856
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of disease and viral biomarkers as triggers for therapeutic intervention in respiratory mousepox - an animal model of smallpox.
Parker S; Chen NG; Foster S; Hartzler H; Hembrador E; Hruby D; Jordan R; Lanier R; Painter G; Painter W; Sagartz JE; Schriewer J; Mark Buller R
Antiviral Res; 2012 Apr; 94(1):44-53. PubMed ID: 22381921
[TBL] [Abstract][Full Text] [Related]
12. A human recombinant analogue to plasma-derived vaccinia immunoglobulin prophylactically and therapeutically protects against lethal orthopoxvirus challenge.
Parker S; D'Angelo J; Buller RM; Smee DF; Lantto J; Nielsen H; Jensen A; Prichard M; George SL
Antiviral Res; 2021 Nov; 195():105179. PubMed ID: 34530009
[TBL] [Abstract][Full Text] [Related]
13. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
Quenelle DC; Collins DJ; Kern ER
Antiviral Res; 2004 Jul; 63(1):33-40. PubMed ID: 15196818
[TBL] [Abstract][Full Text] [Related]
14. Bioterrorism. Blocking smallpox: a second defense.
Cohen J
Science; 2001 Oct; 294(5542):500. PubMed ID: 11641477
[No Abstract] [Full Text] [Related]
15. A review of compounds exhibiting anti-orthopoxvirus activity in animal models.
Smee DF; Sidwell RW
Antiviral Res; 2003 Jan; 57(1-2):41-52. PubMed ID: 12615302
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and Efficacy of a Potential Smallpox Therapeutic, Brincidofovir, in a Lethal Monkeypox Virus Animal Model.
Hutson CL; Kondas AV; Mauldin MR; Doty JB; Grossi IM; Morgan CN; Ostergaard SD; Hughes CM; Nakazawa Y; Kling C; Martin BE; Ellison JA; Carroll DS; Gallardo-Romero NF; Olson VA
mSphere; 2021 Feb; 6(1):. PubMed ID: 33536322
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of inhaled cidofovir as postexposure prophylactic in an aerosol rabbitpox model.
Verreault D; Sivasubramani SK; Talton JD; Doyle LA; Reddy JD; Killeen SZ; Didier PJ; Marx PA; Roy CJ
Antiviral Res; 2012 Jan; 93(1):204-8. PubMed ID: 22146565
[TBL] [Abstract][Full Text] [Related]
18. A single cidofovir treatment rescues animals at progressive stages of lethal orthopoxvirus disease.
Israely T; Paran N; Lustig S; Erez N; Politi B; Shafferman A; Melamed S
Virol J; 2012 Jun; 9():119. PubMed ID: 22709563
[TBL] [Abstract][Full Text] [Related]
19. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
Kornbluth RS; Smee DF; Sidwell RW; Snarsky V; Evans DH; Hostetler KY
Antimicrob Agents Chemother; 2006 Dec; 50(12):4038-43. PubMed ID: 16982794
[TBL] [Abstract][Full Text] [Related]
20. Using biomarkers to stage disease progression in a lethal mousepox model treated with CMX001.
Parker S; Schriewer J; Oberle C; Robertson A; Lanier R; Painter G; Buller RM
Antivir Ther; 2008; 13(7):863-73. PubMed ID: 19043920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
